Skip to content
PeptideFactSheets
Plain-English comparison

Mitochondrial peptides compared: medicine versus early biology

How FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

The quick overview

Elamipretide, MOTS-c, and Humanin all appear in discussions of mitochondria, energy, muscle function, and aging, but they occupy completely different evidence categories.

Forzinity, an elamipretide product, has accelerated FDA approval for a narrow Barth syndrome indication. MOTS-c and Humanin remain largely preclinical research subjects with no FDA-approved drug product and no established human wellness or longevity benefit.

Side-by-side comparison

Elamipretide
FDA approved for specific usesModerate human evidence

Studied for

Barth syndrome · Primary mitochondrial myopathy · Mitochondrial function and muscle energetics

MOTS-c
Preclinical researchMostly animal or lab research

Studied for

Insulin sensitivity and metabolic regulation in animal models · Exercise adaptation and physical capacity · Age-related metabolic decline

Humanin
Preclinical researchMostly animal or lab research

Studied for

Neuroprotection in laboratory and animal models · Cognitive aging associations · Metabolic and insulin-signaling biology

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

What researchers are studying

  • Rare mitochondrial disease and muscle strength
  • Metabolic and exercise signaling
  • Cell survival and neuroprotection
  • Age-related decline and healthy-aging mechanisms

Risks and reasons for caution

  • An FDA approval based on a small rare-disease program cannot be generalized to healthy people or other mitochondrial conditions.
  • Natural blood levels, genetic associations, cells, and animal models do not establish a benefit from taking a peptide product.
  • FDA identifies major human-exposure and product-quality gaps for compounded MOTS-c.

What remains uncertain

  • Whether Forzinity's registered confirmatory trial will verify patient-centered clinical benefit
  • Whether administered MOTS-c or Humanin can improve any clinical human outcome
  • Long-term safety and the relevance of preclinical aging findings to people

Questions to ask a healthcare professional

1. Is the claim tied to the exact peptide, formulation, and population studied?

2. Is the evidence a human outcome, a biomarker, or a cell or animal result?

3. Does the claimed benefit match the narrow approved use, if any?

4. What human safety data exist for the actual product?

Plain-English takeaway

Mitochondrial biology is a research frontier, not a shared clinical indication. Elamipretide has one narrow accelerated approval; MOTS-c and Humanin do not yet have direct evidence as human therapies.

ComparePeptides for muscle growth and performance: what human evidence showsWhy growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.ComparePeptides for cognition and brain research: evidence versus nootropic claimsA status-first comparison of Semax, Selank, oxytocin, and Humanin for cognition, social functioning, anxiety, and neuroprotection.

References

  1. 1
    fdaFDA prescribing information: Forzinity

    Approval scope, intermediate endpoint, warnings, and evidence for elamipretide.

  2. 2
    fdaFDA: selected compounded-peptide safety risks

    FDA summary of human-exposure, immune, impurity, and product-characterization gaps for MOTS-c.

  3. 3
    clinical trialsClinicalTrials.gov: 4TAZPower

    Registered post-marketing confirmatory trial for elamipretide in Barth syndrome.

  4. 4
    pubmedMOTS-c metabolic research

    Preclinical metabolic study that cannot establish human treatment benefit.

  5. 5
    pubmedHumanin cognitive-aging research

    Cell, animal, and human association evidence—not a human treatment trial.